Zydelig: targeted B-cell malignancy treatment

Zydelig (idelalisib) can be used as monotherapy for follicular lymphoma refractory to two prior lines of treatment, and in combination with rituximab for chronic lymphocytic leukaemia after one prior therapy or first-line in patients with the 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy.

The usual dose of Zydelig (idelalisib) is 150mg twice daily continued until disease progression or unacceptable toxicity occurs.
The usual dose of Zydelig (idelalisib) is 150mg twice daily continued until disease progression or unacceptable toxicity occurs.

Idelalisib is a first-in-class oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, an enzyme that is overexpressed in B-cell malignancies and has a role in the viability, proliferation and migration of these cancer cells.

Twice-daily dosing

The usual dose of Zydelig is 150mg twice daily continued until disease progression or unacceptable toxicity occurs. Treatment should be withheld if the patient develops severe diarrhoea/colitis, pneumonitis, rash or if liver enzymes are significantly raised. When the adverse reaction has suitably resolved, patients can restart Zydelig at a reduced dose of 100mg twice daily which can then be increased to 150mg twice daily if appropriate.

'Overwhelming efficacy'

Investigators assessed the efficacy and safety of idelalisib in refractory chronic lymphocytic leukaemia in a randomised, double-blind placebo-controlled phase III study. Patients (n=220) were eligible if they were unable to receive cytotoxic chemotherapy because of renal impairment, major co-existing illness or if they had developed myelosuppression from previous therapy.

Participants were randomised to receive 8 cycles of rituximab plus continuous idelalisib (150g twice daily) or placebo. The primary endpoint was progression-free survival (PFS).

At the first prespecified interim analysis, the study was terminated owing to evidence of overwhelming efficacy with idelalisib.

At 24 weeks, the PFS rate was 93% in the idelalisib group compared with 46% in the placebo group (adjusted HR for progression or death in the idelalisib group, 0.15, 95% CI 0.08-0.28, p<0.001). The median duration of PFS was 5.5 months in the placebo group but was not reached in the idelalisib group. The overall survival rate in patients treated with idelalisib was also superior to that in patients who received placebo (92% vs 80% at 12 months).

In a single-group, open label phase II study, 125 patients with indolent non-Hodgkin's lymphoma who had not responded to rituximab and an alkylating agent, or had relapsed following treatment, were given idelalisib 150mg twice daily as monotherapy until disease progressed or the patient withdrew from the study.

Patients had received a median of four prior therapies and had a median age of 64 years. The response rate (primary endpoint) was 57% (95% CI 48-66%), with 6% of patients meeting the criteria for a complete response. Responses lasted for a median of 12.5 months, and the median duration of PFS was 11 months.

View Zydelig drug record

Further information: Gilead

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.